Nanobiotix (NBTX) Competitors

Nanobiotix has higher revenue and earnings than Apogee Therapeutics.

Nanobiotix has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nanobiotix's return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Nanobiotix currently has a consensus price target of $37.33, suggesting a potential downside of 4.98%. Apogee Therapeutics has a consensus price target of $126.77, suggesting a potential downside of 6.15%. Given Nanobiotix's stronger consensus rating and higher probable upside, equities analysts clearly believe Nanobiotix is more favorable than Apogee Therapeutics.

In the previous week, Apogee Therapeutics had 9 more articles in the media than Nanobiotix. MarketBeat recorded 14 mentions for Apogee Therapeutics and 5 mentions for Nanobiotix. Apogee Therapeutics' average media sentiment score of 1.43 beat Nanobiotix's score of 0.72 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

In the previous week, Alkermes and Alkermes both had 5 articles in the media. Alkermes' average media sentiment score of 0.85 beat Nanobiotix's score of 0.72 indicating that Alkermes is being referred to more favorably in the media.

Alkermes has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Alkermes has higher revenue and earnings than Nanobiotix.

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alkermes currently has a consensus target price of $54.56, suggesting a potential upside of 15.60%. Nanobiotix has a consensus target price of $37.33, suggesting a potential downside of 4.98%. Given Alkermes' stronger consensus rating and higher probable upside, equities analysts clearly believe Alkermes is more favorable than Nanobiotix.

Alkermes has a net margin of 3.96% compared to Nanobiotix's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Nanobiotix's return on equity.

Rhythm Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

38.8% of Nanobiotix shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nanobiotix has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Nanobiotix's return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

In the previous week, Rhythm Pharmaceuticals had 7 more articles in the media than Nanobiotix. MarketBeat recorded 12 mentions for Rhythm Pharmaceuticals and 5 mentions for Nanobiotix. Rhythm Pharmaceuticals' average media sentiment score of 1.70 beat Nanobiotix's score of 0.72 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Rhythm Pharmaceuticals presently has a consensus price target of $141.12, suggesting a potential upside of 34.73%. Nanobiotix has a consensus price target of $37.33, suggesting a potential downside of 4.98%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Rhythm Pharmaceuticals is more favorable than Nanobiotix.

Nanobiotix has lower revenue, but higher earnings than Rhythm Pharmaceuticals.

In the previous week, Scholar Rock had 5 more articles in the media than Nanobiotix. MarketBeat recorded 10 mentions for Scholar Rock and 5 mentions for Nanobiotix. Scholar Rock's average media sentiment score of 1.65 beat Nanobiotix's score of 0.72 indicating that Scholar Rock is being referred to more favorably in the news media.

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Nanobiotix has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Nanobiotix has higher revenue and earnings than Scholar Rock.

Nanobiotix's return on equity of 0.00% beat Scholar Rock's return on equity.

Nanobiotix presently has a consensus price target of $37.33, indicating a potential downside of 4.98%. Scholar Rock has a consensus price target of $58.77, indicating a potential upside of 5.15%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts clearly believe Scholar Rock is more favorable than Nanobiotix.